ADC Therapeutics SA
1.22USD
-0.0800 (-6.15%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 74.9M | 69.1M | 70.8M | 81.4M | 80.6M | 102.0M |
| Q1 | — | 19.0M | 17.8M | 17.4M | 20.0M | — |
| Q2 | — | 19.2M | 17.0M | 18.1M | 18.6M | — |
| Q3 | — | 14.3M | 18.0M | 15.8M | 18.9M | — |
| Q4 | — | 16.6M* | 17.9M* | 30.1M* | 22.1M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.01 | -2.94 | -1.62 | -1.12 | -.760 | -.677 |
| Q1 | — | -.730 | -.560 | -.360 | -.210 | — |
| Q2 | — | -.600 | -.380 | -.500 | -.110 | — |
| Q3 | — | -.570 | -.420 | -.300 | -.212 | — |
| Q4 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -1.04* |
| -.316* |
| -.050* |
| -.202 |
| — |